Global Constipation Treatment Market By Drug Type (Laxatives, Stool Softeners, Lubricants and Others), By Treatment Type (Oral Medications, Enemas, Rectal Suppositories and Others), By Formulation (Tablets, Liquid, Powder and Others), By Distribution Channel (Hospitals & Clinics, Pharmacies & Drugstores and Online Pharmacies), By End-User (Adult Patients, Pediatric Patients, and Geriatric Patients), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034

Report Overview

Global Constipation Treatment Market size is expected to be worth around US$ 22.13 Billion by 2034 from US$ 11.56 Billion in 2024, growing at a CAGR of 6.7% during the forecast period 2025 to 2034. In 2024, North America led the market, achieving over 37.8% share with a revenue of US$ 4.37 Billion.

The constipation treatment market is experiencing significant growth, driven by factors such as the increasing prevalence of constipation worldwide, particularly among the elderly, and the rising awareness surrounding digestive health. Constipation affects a large segment of the global population, with lifestyle changes, inadequate fiber intake, medications, and aging contributing to its widespread occurrence. As more individuals seek relief from this condition, the market for over-the-counter (OTC) and prescription treatments, including laxatives, stool softeners, and fiber supplements, is expanding.

Key players in the market offer a range of products, from oral medications like laxatives and stool softeners to natural remedies such as fiber-rich supplements and probiotics. The growing trend towards natural treatments is driving the demand for non-pharmaceutical options, with consumers becoming more health-conscious and seeking solutions with fewer side effects. The increasing use of digital health solutions, including apps and telemedicine, is another trend that is shaping the market. These technologies enable individuals to track their symptoms and receive personalized treatment recommendations, contributing to a more integrated approach to constipation management.

For instance, in January 2025, a research team at Augusta University Medical Center, Georgia, invited 1,075 patients prescribed vibrating capsule therapy to download an app that tracked five bowel-related metrics: frequency of bowel movements, complete spontaneous bowel movements, stool consistency, straining effort, and time spent on the toilet.

They compared those who used the app with those who did not. The first community-based assessment of real-world use found that the app helped improve therapy compliance and outcomes. At ACG 2024 (abstract P4074), Dr. Rao reported that 453 patients (42%) downloaded the app, with 58 (13%) using it for eight or more weeks. This group was twice as likely to order a refill compared to non-users (68% vs. 34%; P<0.0001) and showed significant improvements in all bowel symptoms from the baseline.

Key Takeaways

• In 2024, the market for Constipation Treatment generated a revenue of US$ 56 Billion, with a CAGR of 6.7%, and is expected to reach US$ 22.13 Billion by the year 2034.
• The Drug Type segment is divided into Laxatives, Stool Softeners, Lubricants, and Others with Laxatives taking the lead in 2023 with a market share of 55.2%.
• By Treatment Type, the market is bifurcated into Oral Medications, Enemas, Rectal Suppositories, and Others, with Oral Medications leading the market with 65.0% of market share.
• Furthermore, concerning the Formulation segment, the market is segregated into Tablets, Liquid, Powder and Others. The Tablets stands out as the dominant segment, holding the largest revenue share of 40.80% in the Constipation Treatment market.
• Considering the Distribution Channel, the market is classified into Hospitals & Clinics, Pharmacies & Drugstores, Online Pharmacies, and Others, with Pharmacies & Drugstores taking the lead with 50.0% market share in 2024.
• By End-User, the market I bifurcated into Adult Patients, Pediatric Patients, and Geriatric Patients, with Adult Patients dominating the market with 55.8% market share.
• North America led the market by securing a market share of 37.8% in 2024.

Drug Type Analysis

Laxatives dominated the constipation treatment market with 55.2% market share due to their wide availability, effectiveness, and strong consumer demand. Laxatives work by stimulating bowel movements or softening stool, which makes them a go-to solution for people suffering from constipation. They come in various forms, including stimulant laxatives, osmotic laxatives, and bulk-forming laxatives, catering to different types of constipation. Their dominance is further fueled by the rising number of individuals dealing with chronic constipation, especially among the elderly population.

The growing awareness of digestive health and the availability of OTC laxatives further drive their usage. Additionally, the convenience and ease of access to laxatives contribute to their popularity, as they are often available without a prescription. As the most commonly used treatment option for constipation, laxatives are expected to maintain their market leadership, with a broad consumer base seeking immediate relief from symptoms.

Treatment Analysis

Oral medications, including both prescription and OTC treatments, dominated the constipation treatment market accounting for over 65.0% market share in 2024 due to their convenience and effectiveness. Oral medications such as laxatives, stool softeners, and fiber supplements are widely available and offer ease of use, as they require no special application methods. The growing trend towards self-medication for digestive issues, along with the ease of purchasing oral medications from pharmacies or online, has fueled the demand for this treatment type.

Oral medications are especially popular among adults who prefer non-invasive treatments to manage mild or chronic constipation. The growing preference for OTC products, combined with advancements in formulations that provide faster and more effective results, further cements the dominance of oral medications in this segment.

Formulation Analysis

Tablets are the leading formulation in the constipation treatment market accounting for over 40.8% market share in 2024, owing to their convenience, long shelf life, and ease of dosing. They are available in a variety of forms, including laxatives, stool softeners, and fiber supplements, and are widely preferred for their ease of storage and transport. The ability to provide a precise dosage makes tablets highly popular among consumers, especially those seeking a consistent and reliable solution for constipation.

Additionally, the global preference for oral treatment options, coupled with the growing demand for self-care products, enhances the position of tablets in the market. Tablets are also favored by individuals who may not want to consume liquid formulations or powders. This formulation is expected to continue dominating the market, especially as more advanced, faster-acting tablets are developed to meet consumer demands for effective and convenient treatment options.

Distribution Channel Analysis

Pharmacies and drugstores are the dominant distribution channels in the constipation treatment market with a 50.0% market share, as they provide direct access to a wide range of products. Consumers can easily purchase constipation treatments, including OTC laxatives, stool softeners, and fiber supplements, in both chain and independent pharmacies. The accessibility of these stores, combined with the increasing trend of self-medication, drives their dominance in the market.

Pharmacies are also trusted sources for recommendations and guidance from pharmacists, which adds to their appeal. As convenience and accessibility are key factors for consumers, the availability of a wide range of products in drugstores continues to drive their market leadership. With the growth of retail pharmacy chains and the expansion of their online platforms, pharmacies and drugstores will remain a critical distribution channel in the years ahead.

End-User Analysis

Adult patients represent the dominant end-user group in the constipation treatment market accounting for 55.80% market share in 2024, largely due to the high prevalence of constipation in this demographic. Factors such as poor dietary habits, sedentary lifestyles, stress, and the use of medications for chronic conditions contribute to the widespread occurrence of constipation in adults. The demand for quick and effective relief drives adults to seek over-the-counter and prescription treatments.

Additionally, the availability of various treatment options tailored to different severity levels of constipation makes it easier for adult patients to find suitable solutions. While geriatric patients and pediatric patients also represent significant segments, adults continue to dominate the market, driven by the high incidence of constipation across various age groups within this category. As the adult population continues to grow, especially in urban areas, the demand for constipation treatments is expected to remain strong.

Key Market Segments

By Drug Type

• Laxatives
• Stool Softeners
• Lubricants
• Others

By Treatment Type

• Oral Medications
• Enemas
• Rectal Suppositories
• Others

By Formulation

• Tablets
• Liquid
• Powder
• Others

By Distribution Channel

• Hospitals & Clinics
• Pharmacies & Drugstores
• Online Pharmacies
• Others

By End-User

• Adult Patients
• Pediatric Patients
• Geriatric Patients

Drivers

Increasing Geriatric Population

The rising global geriatric population is a significant driver for the constipation treatment market. Older adults often experience constipation due to factors such as reduced physical activity, lower fluid intake, medications, and age-related changes in gastrointestinal (GI) function. According to the World Health Organization (WHO), the number of people aged 60 years and older is expected to more than double by 2050. As the elderly population grows, so does the incidence of chronic constipation and related health issues, thereby increasing the demand for effective treatments.

Additionally, seniors are more likely to have multiple underlying health conditions, such as diabetes and cardiovascular diseases, which may require the use of medications that can lead to constipation. These factors collectively drive the market for laxatives, stool softeners, and other constipation relief products. The convenience of over-the-counter treatments for constipation and the growing awareness of the availability of different treatment options further accelerate the market’s growth.

In February 2025, the WHO reported that global life expectancy at birth reached 73.3 years in 2024, reflecting an increase of 8.4 years since 1995. The number of people aged 60 and older is projected to grow from 1.1 billion in 2023 to 1.4 billion by 2030, with this trend accelerating notably in developing regions.

Restraints

Side Effects of Laxatives

Despite their effectiveness, the use of laxatives, especially over long periods, often comes with side effects such as dehydration, electrolyte imbalances, and dependence. These adverse effects can cause concerns among both healthcare providers and patients, limiting the widespread adoption of some constipation treatments. Overuse of laxatives can lead to worsening bowel dysfunction, triggering a cycle of dependency where individuals rely on external aids for bowel movement.

The potential for side effects, especially in vulnerable populations such as the elderly or those with pre-existing medical conditions, may restrict the growth of the market. Furthermore, increasing awareness of the risks associated with laxative overuse may prompt healthcare professionals to recommend alternative, more natural treatments. This can hinder the demand for certain products in the market, especially for those intended for long-term use. The side effects associated with prescription medications and OTC laxatives are major challenges that affect market expansion, limiting the adoption of some products despite their wide availability.

Opportunities

Growing Awareness of Gut Health and Natural Remedies

There is a rising consumer awareness of gut health and the importance of maintaining a healthy digestive system. This trend is especially evident among younger consumers who are increasingly opting for natural and holistic treatments for common ailments like constipation. Probiotics, fiber-rich supplements, and herbal remedies are gaining popularity as they offer safer alternatives to traditional laxatives, with fewer side effects. Studies have shown that probiotics can improve gut motility and restore the balance of the microbiome, which helps in easing constipation.

Similarly, dietary fibers, available in various forms such as powders and capsules, are being embraced for their role in promoting bowel regularity without the risk of dependency. This shift toward natural remedies is an opportunity for companies to diversify their product offerings and appeal to health-conscious consumers. With more focus on preventative care and self-management of health, the market is likely to witness a surge in the demand for non-pharmaceutical constipation treatments, especially those that promote overall digestive health.

In November 2024, Genestra Brands, a trusted Canadian provider of professional-grade nutritional supplements and a leader in the probiotics category, announced the launch of its second annual “Gut Check” campaign. This comprehensive six-episode series is aimed at educating and empowering Canadians on the essential role of gut health in overall wellness. In collaboration with renowned healthcare practitioners Bisleen Attli, Naturopathic Doctor, Clinical Director, and TEDx Speaker, and Carley Nadine McConkey, Holistic Nutritionist, the series seeks to debunk myths and simplify the complexities of gut health, providing reliable, science-backed information.

Impact of Macroeconomic / Geopolitical Factors

Macroeconomic and geopolitical factors play a significant role in shaping the constipation treatment market. Economic conditions, such as inflation, employment rates, and healthcare expenditure, directly influence consumer spending on healthcare products, including constipation treatments. In times of economic downturn or recession, individuals may become more price-sensitive and opt for cost-effective OTC treatments over expensive prescription medications, which can shift the demand dynamics in the market. Economic instability in certain regions can also lead to fluctuations in healthcare budgets, potentially reducing access to specialized treatments, especially in low-income or developing countries.

Geopolitical factors, such as international trade relations and regulations, can also impact the availability and pricing of constipation treatments. Trade barriers, tariffs, and import restrictions can disrupt the supply chain for pharmaceutical products, leading to shortages or increased costs for certain treatments. For instance, global trade disruptions caused by geopolitical tensions may affect the supply of raw materials for manufacturing laxatives or other related products.

Additionally, geopolitical stability influences the development and approval of new treatments. Political factors can impact the regulatory processes, which may either speed up or delay the launch of innovative products in certain markets. In regions with unstable political climates, healthcare infrastructure may also suffer, limiting access to treatments and slowing market growth. In contrast, positive macroeconomic factors such as growing disposable incomes, especially in emerging markets, lead to an increased demand for healthcare products, including constipation treatments. Furthermore, increasing healthcare investments in developing economies open new market opportunities, enhancing growth potential for constipation treatment manufacturers.

Latest Trends

Increasing Use of Digital Health Solutions for Treatment Monitoring

One of the emerging trends in the constipation treatment market is the growing use of digital health solutions for managing and monitoring bowel health. Apps, wearables, and telemedicine platforms are gaining traction, allowing patients to track their symptoms, bowel movements, diet, and medication use more effectively. These digital tools not only assist individuals in managing their constipation symptoms but also provide healthcare professionals with real-time data, improving treatment outcomes.

Moreover, telemedicine consultations allow patients, particularly those in remote areas, to access healthcare professionals who can recommend personalized treatments. The increasing adoption of digital health solutions in managing constipation is also helping reduce the stigma around the condition, enabling patients to track and address issues in a private and accessible manner. This trend is expected to drive the market for digital health apps and related devices, creating a more integrated approach to constipation treatment. As patients and healthcare providers become more reliant on technology, this trend will likely lead to more innovative solutions for managing and treating constipation.

For instance, in October 2024, Fortis Hospital Gurugram has launched North India’s first Advanced Constipation & Pelvic Clinic, integrating state-of-the-art equipment, cutting-edge technology, and expert gastroenterology care. Led by Dr. Gourdas Choudhuri, Chairman of Gastroenterology, alongside Dr. Rinkesh Bansal, Additional Director, and Dr. Zubin Dev Sharma, Senior Consultant, the clinic has partnered with JOGO Health Pvt Ltd, a U.S.-based digital therapeutics company. This collaboration introduces JOGO’s EMG biofeedback technology, providing non-invasive solutions for chronic constipation, urinary and fecal incontinence, pelvic organ prolapse, and voiding dysfunction.

Regional Analysis

North America is leading the Constipation Treatment Market

The constipation treatment market in North America held 37.8% market share which is experiencing steady growth due to the increasing prevalence of digestive health issues and an aging population. More people are seeking treatments for constipation, particularly as lifestyle factors like poor diet, lack of exercise, and stress contribute to the condition. Constipation is a prevalent digestive issue in the United States, impacting individuals of all ages, especially those over 60.

According to the National Institutes of Health (NIH), around 16% of adult experience constipation, with the rate increasing to 33% for those aged 60 and older. Chronic constipation is estimated to affect 15% of the population. The growing number of elderly individuals, who are more prone to constipation, is also fueling the demand for effective treatments. Moreover, awareness of gastrointestinal health is rising, leading consumers to explore various over-the-counter and prescription options for relief.

As a result, the market is seeing greater demand for products like laxatives, stool softeners, and fiber supplements. Innovations in treatment options, along with the rise of digital health solutions for managing symptoms, are further contributing to market expansion. With a focus on developing more effective, faster-acting, and natural remedies, the North American market is expected to continue its growth in the coming years.

Key Regions and Countries

North America

• US
• Canada

Europe

• Germany
• France
• The UK
• Spain
• Italy
• Russia
• Netherland
• Rest of Europe

Asia Pacific

• China
• Japan
• South Korea
• India
• Australia
• New Zealand
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE
• Rest of MEA

Key Players Analysis

Key players in the Constipation Treatment market includes Procter & Gamble Co., AbbVie Inc., Bayer AG, GlaxoSmithKline Plc, Johnson & Johnson, Sanofi S.A., Takeda Pharmaceutical Company Limited, Mylan N.V., Abbott Laboratories, Perrigo Company plc, C.B. Fleet Company, Inc., Ferring Pharmaceuticals, AstraZeneca Plc, Novartis International AG, Sandoz, Mallinckrodt Pharmaceuticals, Hikma Pharmaceuticals, S.C. Johnson & Son, Inc., and Other key players.

Procter & Gamble (P&G) is a prominent player in the North American constipation treatment market, primarily through its brand Metamucil. Metamucil is a fiber supplement containing psyllium seed husks, which is widely used to promote digestive health and relieve constipation. P&G markets Metamucil in various forms, including powders, capsules, and wafers, catering to diverse consumer preferences. AbbVie is a key player in the prescription constipation treatment market, known for its product LINZESS® (linaclotide).

LINZESS is a guanylate cyclase-C agonist approved for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults.  Bayer AG is a notable participant in the over-the-counter constipation treatment market, particularly through its brand MiraLAX®. MiraLAX is an osmotic laxative that works by drawing water into the colon, softening stool, and making bowel movements more comfortable. Unlike stimulant laxatives, MiraLAX provides gentle relief without causing harsh side effects such as gas, bloating, or cramping.

Top Key Players

• Procter & Gamble Co.
• AbbVie Inc.
• Bayer AG
• GlaxoSmithKline Plc
• Johnson & Johnson
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Mylan N.V.
• Abbott Laboratories
• Perrigo Company plc
• B. Fleet Company, Inc.
• Ferring Pharmaceuticals
• AstraZeneca Plc
• Novartis International AG
• Sandoz
• Mallinckrodt Pharmaceuticals
• Hikma Pharmaceuticals
• C. Johnson & Son, Inc.
• Other key players

Recent Developments

• In May 2025, Shionogi & Co., Ltd. has announced that China has accepted the New Drug Application (NDA) for naldemedine tosilate (naldemedine), a treatment for opioid-induced constipation (OIC). Developed by the company, naldemedine is a peripherally acting μ-opioid receptor antagonist (PAMORA). It has already been launched in countries such as Japan, the United States, Europe, and Taiwan, significantly helping improve symptoms for many patients dealing with opioid-induced constipation.
• In October 2024, Dr. Reddy’s Laboratories launched Elobixibat, a first-in-class drug for treating chronic constipation, in India. The drug will be marketed under the brand name BixiBat. This launch follows approval from the Central Drugs Standard Control Organisation (CDSCO), which was granted after Dr. Reddy’s successful Phase-3 clinical trial submission to the CDSCO’s Subject Expert Committee. Dr. Reddy’s is the first company to receive approval for and introduce Elobixibat in India.
• In June 2023, the FDA has approved Linzess (linaclotide) capsules for the treatment of functional constipation in pediatric patients aged 6 to 17 years. Linzess becomes the first treatment specifically approved for pediatric functional constipation. The recommended dosage for this age group is 72 mcg orally once daily.

Report Scope